Announcements Trials
Browse Landscape

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Papilloma 1Neoplasms, Squamous Cell 1Neoplasms, Glandular and Epithelial 1Neoplasms by Histologic Type 1Neoplasms 1

Interventions

pembrolizumab 184Carboplatin 130Paclitaxel 123Gemcitabine 122Docetaxel 96Cyclophosphamide 89Nivolumab 88Cisplatin 87Rituximab 71Dexamethasone 68Pemetrexed 64Bevacizumab 64Capecitabine 60atezolizumab 54fludarabine 49Azacitidine 49Fluorouracil 48130-nm albumin-bound paclitaxel 43venetoclax 41Trastuzumab 41Irinotecan 41Cetuximab 40Leucovorin 36Ipilimumab 36Erlotinib Hydrochloride 34Fulvestrant 32Cytarabine 32avelumab 31Oxaliplatin 31Albumin-Bound Paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × INDUSTRY × Papanicolaou Test × Clear all
NCT01234480 2023-05-16

Intended Use Study of the BD SurePath Plusâ„¢ Pap

Becton, Dickinson and Company

Terminated
5,859 enrolled 4 charts
Gynecologic

Uterine Cervical Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Papilloma, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡